Senzar Asset Management Llc Lowered Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI) as Price Declined

May 17, 2018 - By Dominique Gillenwater

During Q4 2017 the big money sentiment decreased to 1.2. That’s change of 0.53, from 2017Q3’s 1.73. 23 investors sold all, 48 reduced holdings as AERI ratio turned negative. 64 grew holdings while 21 funds bought holdings. Funds hold 34.86 million shares thus 1.29% more from 2017Q3’s 34.42 million shares. Principal Fincl Gp Inc holds 15,406 shs or 0% of its capital. Neuberger Berman Ltd Company has invested 0.02% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Bailard stated it has 22,650 shs or 0.09% of all its holdings. Endurant Cap Mngmt Limited Partnership invested 0.83% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Glenmede Trust Na reported 0% stake. Price T Rowe Associates Incorporated Md owns 327,671 shs. Alyeska Investment Group Limited Partnership has invested 0.07% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Polar Capital Ltd Liability Partnership owns 100,000 shs for 0.06% of their capital. Loomis Sayles And L P holds 276,730 shs or 0.03% of its capital. Bankshares Of America Corporation De owns 36,815 shs. Dekabank Deutsche Girozentrale reported 15,900 shs. Qs Investors Ltd Liability Company reported 0% stake. Royal Savings Bank Of Canada accumulated 30,364 shs. Prudential Financial reported 53,020 shs or 0% of all its holdings. New York-based Tocqueville Asset Lp has invested 0.1% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Based on the latest 2018Q1 regulatory filing with the SEC, Senzar Asset Management Llc decreased its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 74.62%. The company’s stock Sank 12.77% while Senzar Asset Management Llc sold 207,732 shares. At the end of 2018Q1, the 70,668 shares of the health care company held by the hedge fund were priced at $3.83M, down from 278,400 at the end of the previous reported quarter. $2.02B is the MC of Aerie Pharmaceuticals Inc. AERI reached $51.2 during the last trading session after $0.8 change.Currently Aerie Pharmaceuticals, Inc. is uptrending after 16.25% change in last May 17, 2017. AERI has 224,990 shares volume. AERI outperformed the S&P500 by 4.70%.

For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .

Senzar Asset Management Llc is a New York-based hedge fund with more than $442.00 million AUM in December, 2014. Taken from Senzar Asset Management latest Adv, the fund reported to have 7 full and part-time employees. Among which 4 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Total analysts of 6 have positions in Aerie Pharma (NASDAQ:AERI) as follows: 6 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 18, 2017 according to StockzIntelligence Inc Aerie Pharma has 11 analyst reports. On Wednesday, May 9 Mizuho maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating. Mizuho has “Buy” rating and $7700 target. In Tuesday, May 8 report Cantor Fitzgerald maintained it with “Buy” rating and $8600 target. On Monday, December 18 the stock has “Buy” rating by Cantor Fitzgerald. On Friday, February 16 the firm has “Buy” rating by H.C. Wainwright given. On Thursday, March 1 the firm earned “Buy” rating by H.C. Wainwright. On Thursday, March 29 Mizuho maintained the shares of AERI in report with “Buy” rating. The company rating was maintained by Canaccord Genuity on Wednesday, January 24. The company rating was maintained by Cantor Fitzgerald on Wednesday, February 28. On Tuesday, January 2 the stock has “Buy” rating by Stifel Nicolaus. On Wednesday, May 9 the stock has “Buy” rating by H.C. Wainwright.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is valued at $2.02 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Currently it has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: